Redenlab brings on Dr Amir Lahav as Chief of Digital Health and Strategy

Redenlab extend their reach in the #speech neuroscience and clinical trials by adding #leaders at the forefront of #digitalhealth & #virtualtrials. Formerly with Pfizer & Harvard University, Amir Lahav brings 15+ years of experience in the healthcare industry, academic research, clinical data science, and Around the Pill solutions.

Dr Amir Lahav is a clinical neuroscientist and a leading innovator in digital health with a special focus on developing and validating novel biomarkers and AI-driven technology for remote monitoring of patients with neurodegenerative diseases. Amir has 15+ years of experience in the healthcare industry, academic research, clinical data science, and Around the Pill solutions. He is currently the Head of R&D at Mitsubishi Tanabe Pharma Holding America, and a freelance consultant for several HealthTech companies in the DTx space. Formerly, Amir served as the Head of Digital Innovation at Pfizer’s Rare Disease Unit, where he led the development of technology solutions and mobile health apps, from proof-of-concept studies to global scale-up implementation in clinical trials. Prior to pharma, Amir was a professor of pediatrics at Harvard Medical School and a PI on multiple technology-driven clinical trials. Amir leads Redenlab’s digital health & strategy, driving innovation in new markets and disease groups.

Related Post

  • Posted on 17 June, 2024
    Up to half of all people with multiple sclerosis experience communication difficulties due to dysarthria, a disorder that impacts the...
    • Posted on 12 June, 2024
      Frontotemporal Dementia (FTD) encompasses a range of progressive neurodegenerative conditions that impair speech production and comprehension, higher cognitive functions, behavior,...
      • Posted on 7 June, 2024
        Redenlab’s CEO, Adam Vogel, co-wrote "The Role of Verbal Fluency in the Cerebellar Cognitive Affective Syndrome Scale in Friedreich Ataxia"...